Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

Obesity Treatments

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

The $14-per-share agreement brings Lilly a clinical portfolio targeting chronic inflammation, with closing targeted in the first half of 2026.

Paramount Launches Hostile $30‑a‑Share Bid for Warner Bros. Discovery to Challenge Netflix Agreement